KPC Xuesaitong Pharmaceutical

KPC Pharmaceuticals, formerly known as Kunming Pharmaceutical Group, is a prominent Chinese pharmaceutical company with a history dating back to 1951. The company is a leader in the modernization of Traditional Chinese Medicine (TCM), particularly through its flagship Xuesaitong product line derived from Panax notoginseng. Xuesaitong is widely used in China for the treatment of cardiovascular and cerebrovascular diseases, including stroke and coronary heart disease. KPC is also recognized globally for its pioneering work in artemisinin-based anti-malarial therapies, serving as a major supplier to international health organizations. In 2022, the company became a subsidiary of China Resources Sanjiu (CR Sanjiu), integrating into one of China's largest healthcare conglomerates.